Acadia Pharmaceuticals (ACAD) Profit After Tax (QoQ) (2010 - 2026)
Acadia Pharmaceuticals (ACAD) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 4.37 Bn | 3.51 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.67% |
| Dec 31, 2025 | 281.13% |
| Sep 30, 2025 | 169.18% |
| Jun 30, 2025 | 40.44% |
| Mar 31, 2025 | -86.79% |
| Dec 31, 2024 | 338.71% |
| Sep 30, 2024 | -1.87% |
| Jun 30, 2024 | 101.69% |
| Mar 31, 2024 | -63.85% |
| Dec 31, 2023 | 170.27% |
| Sep 30, 2023 | -5,950.63% |
| Jun 30, 2023 | 102.59% |
| Mar 31, 2023 | -3.11% |
| Dec 31, 2022 | -53.50% |
| Sep 30, 2022 | 20.08% |
| Jun 30, 2022 | 69.92% |
| Mar 31, 2022 | -162.35% |
| Dec 31, 2021 | -198.08% |
| Sep 30, 2021 | 67.05% |
| Jun 30, 2021 | 33.98% |